Silo Pharma is a for-profit, listed, bio-pharma company aiming to commercialize psychedelics.
Silo Pharma
The company is listed on the OTCQB Venture Market. It is working together with Maastricht University on a study with psilocybin and LSD for Parkinson’s.
The company was previously called ‘Uppercut Brands’ and sold ‘urban fashion’ online.
In December 2021, Silo announced it has entered into Securities Purchase Agreements with certain existing institutional and accredited investors for a $4.275 million fixed-price convertible preferred equity financing.
Key Staff
- Eric Weisblum – CEO
- Matthew Johnson – scientific advisor
News
- Silo Pharma Announces Plans for a Phase 2B Investigator Lead Study Using Psychedelics Psilocybin and Lysergic Acid Diethylamide (“LSD”) to Treat Parkinson’s Disease (Psilocybin Alpha, December 2020)
- Silo Pharma, Inc. Launches Scientific Advisory Board with Appointment of Dr. Matthew Johnson of John Hopkins University (Psilocybin Alpha, November 2020)
Activities
B2B
B2C
Pharmaceutical
Explore more company info with a Tree membership
📰 Weekly newsletter about the business of psychedelics
📈 Extended company information (analyst view, fundraising, revenue numbers)
🪄 Priority company page updates